ArticleBiotechnology progress
Application of commercial ultrafiltration membranes for protein purification by high performance countercurrent membrane purification (HPCMP).
Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
High performance countercurrent membrane purification (HPCMP) has emerged as a promising diffusive separation strategy for the purification of recombinant proteins and monoclonal antibodies (mAbs). However, prior studies employed dialysis membranes, which are designed for diffusive separations but have not been validated for biopharmaceutical manufacturing. This study evaluates the ability of commercial ultrafiltration (UF) membranes, engineered for pressure-driven filtration, to support highly selective diffusive separations. Scanning electron microscopy (SEM) analysis of the membrane cross-sections revealed marked morphological differences between UF and dialysis membranes. Yet, transport studies using polydisperse dextrans and model proteins demonstrated that UF membranes can deliver exceptional diffusive separation selectivity. In particular, a 100 kDa polysulfone membrane (Cytiva) provided >150-fold diffusive selectivity between bovine serum albumin (BSA) and immunoglobulin G (IgG). When utilized for mAb separation from a clarified CHO cell culture fluid, this membrane achieved >98% product yield, near-complete removal of low molecular weight species, and significant reduction in both DNA and host cell protein (HCP) levels. These results demonstrate that commercial UF membranes that are validated for bioprocessing applications can be repurposed for HPCMP, enabling scalable, continuous downstream processing of biotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.